Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000554442 | SCV000658553 | likely benign | Familial hyperkalemic periodic paralysis | 2024-08-12 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV005004247 | SCV002784187 | uncertain significance | Potassium-aggravated myotonia; Paramyotonia congenita of Von Eulenburg; Hypokalemic periodic paralysis, type 2; Familial hyperkalemic periodic paralysis; Congenital myasthenic syndrome 16; Congenital myopathy 22A, classic; Congenital myopathy 22B, severe fetal | 2024-01-05 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV003139863 | SCV003821272 | uncertain significance | not provided | 2021-03-24 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004024399 | SCV004944260 | uncertain significance | Inborn genetic diseases | 2023-12-19 | criteria provided, single submitter | clinical testing | The c.3058C>G (p.L1020V) alteration is located in exon 16 (coding exon 16) of the SCN4A gene. This alteration results from a C to G substitution at nucleotide position 3058, causing the leucine (L) at amino acid position 1020 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |